Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded ...
A pending FDA review of several peptides is giving investors a new growth story for Hims as the company resets its U.S. weight-loss business.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results